



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bondarev

Serial No.: 10/758,329

Filed: January 15, 2004

Attorney Docket No.: 04-40018-US

TITLE: MODULATION OF LINE-1  
REVERSE TRANSCRIPTASE**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97(c)(1)**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

It is believed that this Information Disclosure Statement is being filed prior to the mailing date of any final action, a notice of allowance, or an action that otherwise closes prosecution of the application pursuant to 37 C.F.R. §1.97(c)(1).

Each item of information contained in this information disclosure statement was first cited in an International Search Report not more than three months prior to the filing of this information disclosure statement. Therefore, under 37 C.F.R. § 1.97(e)(1) and (c)(1), it is believed no fee is due. However, in the event that there is any fee due or overpayment credited, the Commissioner is hereby authorized to charge fees and credit overpayment to Deposit Account No. 18-0586.

**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10**


EXPRESS MAIL Mailing Label Number: EV 699482069 US

Date of Deposit: May 22, 2006

I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL – POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450


Cody M. McAtee

(Name of person mailing paper.)




(Signature of person mailing paper.)

Respectfully submitted,



Nanda P.B.A. Kumar  
Registration No. 44,853  
**REED SMITH LLP**  
P.O. Box 7990  
Philadelphia, PA 19101-7990  
(215) 241-7991

Attorney for Applicant

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE</b>   <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <b>(37 CFR 1.98(b))</b>	<b>ATTY. DOCKET NO.</b> 04-40018-US	<b>SER. NO.</b> 10/758,329
	<b>APPLICANT</b> Bondarev	
	<b>FILING DATE</b> January 15, 2004	<b>GROUP</b> 1635

**U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					
	BB					
	BC					

**OTHER DOCUMENTS**

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CA	Giordano, et al., "Reverse Transcriptase Activity in Mature Spermatozoa of Mouse", The Journal of Cell Biology, vol. 148, no. 6, March 20, 2000, pp. 1107-1113.
	CB	Mangiacasale, et al., "Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation", Oncogene, vol. 22, 2003, pp. 2750-2761.
	CC	Beraldi, et al, "Expression of LINE-1 Retroposons Is Essential for Murine Preimplantation Development", Molecular Reproduction and Development, vol. 73, 2006, pp. 279-287.
	CD	Soifer, et al., "A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon", Nucleic Acids Research, vol. 33, no. 3, 2005, pp. 846-856.
	CE	Sciamanna, et al., "Inhibition of endogenous reverse transcriptase antagonizes human tumor growth", Oncogene, vol. 24, 2005, pp. 3923-2931.

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.